Related Experiment Video
Updated: Sep 1, 2025
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Knowledge mapping and research hotspots of immunotherapy in renal cell carcinoma: A text-mining study from 2002 to
Kun Liu1, Seling Zhao1, Jian Li1
1Department of Urology, Xiamen Humanity Hospital, Fujian Medical University, Xiamen, China.
Background:
Renal cell carcinoma (RCC) is one of the most lethal urological malignancies, and because early-stage RCC is asymptomatic, many patients present metastatic diseases at first diagnosis. With the development of immunotherapy, the treatment of RCC has entered a new stage and has made a series of progress. This study mainly outlines the knowledge map and detects the potential research hotspots by using bibliometric analysis.
Methods:
Publications concerning RCC immunotherapy from 2002 to 2021 in the Web of Science Core Collection were collected. Visualization and statistical analysis were mainly performed by freeware tools VOSviewer, CiteSpace, R software, and Microsoft Office Excel 2019.
Results:
A total of 3,432 papers were collected in this study, and the annual number of papers and citations showed a steady growth trend. The United States is the leading country with the most high-quality publications and is also the country with the most international cooperation. The University of Texas MD Anderson Cancer Center is the most productive organization. The Journal of Clinical Oncology is the highest co-cited journal, and Brian I. Rini is both the most prolific author and the author with the largest centrality. The current research hotspots may be focused on "immune checkpoint inhibitors (ICIs)," "PD-1," and "mammalian target of rapamycin."
Conclusion:
Immunotherapy has a bright future in the field of RCC treatment, among which ICIs are one of the most important research hotspots. The main future research directions of ICI-based immunotherapy may focus on combination therapy, ICI monotherapy, and the development of new predictive biomarkers.
Insights
This bibliometric analysis reveals key trends in renal cell carcinoma (RCC) immunotherapy research. Immune checkpoint inhibitors (ICIs) are a major focus, with future directions including combination therapies and biomarker development.
Area of Science:
- Urology
- Oncology
- Immunotherapy
Background:
- Renal cell carcinoma (RCC) is a lethal malignancy often diagnosed at advanced stages.
- Immunotherapy has revolutionized RCC treatment, marking a new era in patient care.
- Understanding research trends is crucial for advancing RCC treatment strategies.
Purpose of the Study:
- To outline the knowledge map of RCC immunotherapy research.
- To identify emerging research hotspots and trends in the field.
- To provide insights into future research directions for RCC immunotherapy.
Main Methods:
- Bibliometric analysis of 3,432 publications from 2002-2021 in the Web of Science Core Collection.
- Utilized VOSviewer, CiteSpace, R software, and Microsoft Office Excel for data analysis and visualization.
- Examined publication trends, country/institution productivity, key journals, and influential authors.
Main Results:
- A consistent annual growth in publications and citations related to RCC immunotherapy.
- The United States leads in high-quality publications and international collaboration.
- Key research hotspots identified include immune checkpoint inhibitors (ICIs), PD-1, and mammalian target of rapamycin (mTOR).
Conclusions:
- Immunotherapy, particularly ICIs, holds significant promise for RCC treatment.
- Future research should explore combination therapies, ICI monotherapy, and novel predictive biomarkers.
- Continued investigation into immunotherapy is vital for improving outcomes in renal cell carcinoma patients.
More Related Videos
12:22The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
08:30Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry
Published on: October 9, 2018
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...